AstraZeneca building — health policy coverage from STAT
Raphael Lafargue/Abaca/Sipa USA via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we see a federal agency change its tune on patent thickets, likely because of the incoming administration. Also, a cool mouse study, and a new fund from Atlas Venture.

advertisement

U.S. PTO withdraws new patent thicket proposal

In May, the U.S. Patent & Trademark Office had proposed a rule to crack down on patent thickets — but surprisingly, it has now withdrawn that proposal. The idea had been to curb attempts by biopharma companies to use collections of patents to gain monopolies by preventing generic competitors from entering the marketplace. But the PTO’s proposal was immediately polarizing, and the decision to already withdraw it was thanks to “resource constraints” at the agency — no other explanations offered.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe